Catherine S Hwang
Dados Biográficos
| ID | 8450222 |
|---|---|
| NOME | Catherine S Hwang |
| PRENOMES | Catherine S |
| SOBRENOME | Hwang |
| ASSINATURA | HWANG C S |
| AFILIAÇÕES | Brigham and Women's Hospital |
| ORCID | 0009-0004-0185-3256 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 4 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 4 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2015 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2025 |
| ÍNDICE H | 0 |
Using Trademarks to Ensure Completion of Postapproval Trials
This Viewpoint evaluates how using trademarks can support the US Food and Drug Administration’s mission to approve safe and effective medications
Health Care Spending After Initiating Sacubitril-Valsartan vs Renin-Angiotensin System Blockers for Heart Failure Treatment
This cohort study found that Medicare beneficiaries initiating sacubitril-valsartan to treat HFrEF had similar total health care spending as those initiating ACE-I/ARBs; higher prescription drug spending was offset by lower inpatient and outpatient spending. However, sacubitril-valsartan use was associated with higher patient out-of-pocket costs, which may exacerbate health disparities and limit access and affordability
State Spending Targets for Prescription Drugs
This Viewpoint discusses the limitations of state prescription drug spending targets for lowering medication costs
The Prescription Opioid and Heroin Crisis
Public health authorities have described, with growing alarm, an unprecedented increase in morbidity and mortality associated with use of opioid pain relievers (OPRs). Efforts to address the opioid crisis have focused mainly on reducing nonmedical OPR use. Too often overlooked, however, is the need for preventing and treating opioid addiction, which occurs in both medical and nonmedical OPR users. Overprescribing of OPRs has led to a sharp increa…
Sem obras proeminentes nesta página.
The Prescription Opioid and Heroin Crisis
Public health authorities have described, with growing alarm, an unprecedented increase in morbidity and mortality associated with use of opioid pain relievers (OPRs). Efforts to address the opioid crisis have focused mainly on reducing nonmedical OPR use. Too often overlooked, however, is the need for preventing and treating opioid addiction, which occurs in both medical and nonmedical OPR users. Overprescribing of OPRs has led to a sharp increa…
State Spending Targets for Prescription Drugs
This Viewpoint discusses the limitations of state prescription drug spending targets for lowering medication costs
Using Trademarks to Ensure Completion of Postapproval Trials
This Viewpoint evaluates how using trademarks can support the US Food and Drug Administration’s mission to approve safe and effective medications
Health Care Spending After Initiating Sacubitril-Valsartan vs Renin-Angiotensin System Blockers for Heart Failure Treatment
This cohort study found that Medicare beneficiaries initiating sacubitril-valsartan to treat HFrEF had similar total health care spending as those initiating ACE-I/ARBs; higher prescription drug spending was offset by lower inpatient and outpatient spending. However, sacubitril-valsartan use was associated with higher patient out-of-pocket costs, which may exacerbate health disparities and limit access and affordability
Medicine (3 obras) · Business (2 obras) · Drug (2 obras) · Health Systems, Economic Evaluations, Quality of Life (2 obras) · Medical prescription (2 obras) · Medication Adherence and Compliance (2 obras) · Risk analysis (engineering (2 obras) · Addiction (1 obras) · Administration (probate law (1 obras) · Biomedical Ethics and Regulation (1 obras)